Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS

Reuters

2025/06/05

Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS

Immunic, Inc., a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis $(RMS.AU)$. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541021720"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541021720\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541021720?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541021720","market":"nz","top_or_hot":-1,"title":"Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMUX\">Immunic, Inc.</a>, a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis <a href=\"https://laohu8.com/S/RMS.AU\">$(RMS.AU)$</a>. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMUX\">Immunic, Inc.</a>, a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis <a href=\"https://laohu8.com/S/RMS.AU\">$(RMS.AU)$</a>. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL9J2cVq:1","article_id":"2541021720","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541021720","pubTimestamp":1749119431,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire  on June 05, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IMUX":"Immunic, Inc."},"translate_title":"Immunic Inc.宣布完成复发性MS 3期试验的招募，并强调进行性MS 2期试验的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":0.9},"content_text":"Immunic Inc. Announces Completion of Enrollment for Phase 3 Trials in Relapsing MS and Highlights Positive Phase 2 Results for Progressive MS\n    \n\nImmunic, Inc., a biotechnology company specializing in treatments for chronic inflammatory and autoimmune diseases, has completed enrollment for its phase 3 ENSURE trials for vidofludimus calcium in patients with relapsing multiple sclerosis $(RMS.AU)$. Involving over 2,200 participants, these trials represent a significant milestone toward potential regulatory approval and commercialization. The company expects top-line data by the end of 2026. Additionally, new data from the phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) highlights the neuroprotective potential of vidofludimus calcium, showing substantial reductions in time to 24-week confirmed disability worsening compared to a placebo. Dr. Daniel Vitt, CEO of Immunic, emphasized the drug's promising safety profile and its potential to transform the oral MS therapy market by offering a novel treatment option with neuroprotective, anti-inflammatory, and antiviral effects.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY03900) on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}